FILINGS
| AZN 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2022-09-06 | 6-K | IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER | View Document |
| 2022-09-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-08-30 | 6-K | EVUSHELD APPROVED FOR COVID-19 IN JAPAN | View Document |
| 2022-08-30 | 6-K | FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF | View Document |
| 2022-08-30 | 6-K | FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE | View Document |
| 2022-08-25 | 6-K | ULTOMIRIS APPROVED IN JAPAN FOR GMG | View Document |
| 2022-08-25 | 6-K | TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER | View Document |
| 2022-08-25 | 6-K | LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER | View Document |
| 2022-08-16 | 6-K | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL | View Document |
| 2022-08-15 | 6-K | ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 | View Document |
| 2022-08-12 | 6-K | ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC | View Document |
| 2022-08-11 | 6-K | ACQUISITION OF TENEOTWO COMPLETED | View Document |
| 2022-08-08 | 6-K | ENHERTU APPROVED IN THE US FOR HER2-LOW MBC | View Document |
| 2022-08-04 | 6-K | LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER | View Document |
| 2022-08-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-08-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-29 | 6-K | FORM 6-K | View Document |
| 2022-07-29 | 6-K | CHAIR SUCCESSION | View Document |
| 2022-07-25 | 6-K | TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA | View Document |
| 2022-07-25 | 6-K | ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG | View Document |
| 2022-07-25 | 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC | View Document |
| 2022-07-19 | 6-K | ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC | View Document |
| 2022-07-08 | SC 13G | View Document | |
| 2022-07-05 | 6-K | ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER | View Document |
| 2022-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-06-30 | 6-K | IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER | View Document |
| 2022-06-29 | 11-K | ANNUAL REPORT | View Document |
| 2022-06-27 | 6-K | ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL | View Document |
| 2022-06-27 | 6-K | LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER | View Document |
| 2022-06-21 | 6-K | EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS | View Document |
| 2022-06-10 | 25-NSE | View Document | |
| 2022-06-09 | 25-NSE | View Document | |
| 2022-06-06 | 6-K | ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER | View Document |
| 2022-06-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2022-06-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-09 | 6-K | APPOINTMENT OF JOINT CORPORATE BROKERS | View Document |
| 2022-05-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-05 | 6-K | ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER | View Document |
| 2022-05-05 | 6-K | FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2022-05-05 | 6-K | ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2022-05-04 | 6-K | IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC | View Document |
| 2022-05-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-04-29 | 6-K | RESULT OF AGM | View Document |
| 2022-04-29 | 6-K | ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS | View Document |
| 2022-04-29 | 6-K | FIRST QUARTER 2022 RESULTS | View Document |
| 2022-04-28 | 6-K | ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG | View Document |
| 2022-04-27 | 6-K | ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER | View Document |
| 2022-04-25 | 6-K | TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO | View Document |
| 2022-04-19 | 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC | View Document |
| 2022-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-29 | 6-K | ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL | View Document |
| 2022-03-28 | 6-K | EVUSHELD APPROVED IN THE EU FOR COVID-19 | View Document |
| 2022-03-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-24 | 6-K | EVUSHELD POSITIVE EU CHMP OPINION | View Document |
| 2022-03-24 | 6-K | UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA | View Document |
| 2022-03-23 | 6-K | NOTICE OF AGM | View Document |
| 2022-03-23 | 6-K | FORM 6-K | View Document |
| 2022-03-17 | 6-K | SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS | View Document |
| 2022-03-14 | 6-K | LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER | View Document |
| 2022-03-14 | 6-K | UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS | View Document |
| 2022-03-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-01 | 6-K | ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 | View Document |
| 2022-02-23 | 6-K | FILING OF FORM 20-F WITH SEC | View Document |
| 2022-02-22 | IRANNOTICE | IRANNOTICE | View Document |
| 2022-02-22 | 20-F | FORM 20F | View Document |
| 2022-02-22 | 6-K | CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT | View Document |
| 2022-02-22 | 6-K | ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC | View Document |
| 2022-02-16 | 6-K | SAPHNELO APPROVED IN EU FOR SLE | View Document |
| 2022-02-15 | 6-K | LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE | View Document |
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-10 | 6-K | AZN: FULL YEAR AND Q4 2021 RESULTS | View Document |
| 2022-02-07 | SC 13G/A | View Document | |
| 2022-02-04 | SC 13G/A | SEC SCHEDULE 13G | View Document |
| 2022-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-01-19 | 6-K | IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER | View Document |
| 2022-01-19 | 6-K | IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC | View Document |
| 2022-01-18 | 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER | View Document |
| 2022-01-07 | 6-K | ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 | View Document |
| 2022-01-05 | 6-K | TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED | View Document |
| 2022-01-04 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-12-29 | 6-K | ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL | View Document |
| 2021-12-21 | 6-K | ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG | View Document |
| 2021-12-20 | 6-K | TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA | View Document |
| 2021-12-20 | 6-K | SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE | View Document |
| 2021-12-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-12-09 | 6-K | EVUSHELD US FDA EUA | View Document |
| 2021-12-07 | 6-K | ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN | View Document |
| 2021-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2021-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-11-30 | 6-K | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA | View Document |
| 2021-11-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2021-11-12 | 6-K | AZN: YEAR TO DATE AND Q3 2021 RESULTS | View Document |
| 2021-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-11-01 | 6-K | ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR | View Document |
| 2021-10-25 | 6-K | IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
